Eluxadoline is indicated in adults for the treatment of irritable bowel syndrome with diarrhea (IBS-D).

Eluxadoline is a mu-opioid receptor agonist, kappa opioid receptor agonist, and delta opioid receptor antagonist. Eluxadoline works directly in the intestine to reduce peristalsis and also makes the nerves in the intestine less sensitive to stimulation.

The recommended dose is 75 mg tablet taken orally twice daily with food. Patients who develop severe constipation for more than 4 days have to discontinue the drug. If a dose is missed, patient should take the next dose at the regular time and avoid taking two doses at a time.

Pediatric Use: Safety and effectiveness in pediatric patients have not been established.

Hepatic Impairment: It is contraindicated in patients with severe hepatic impairment.

Oral Contraceptive, Cyclosporine, Probenecid, Rosuvastatin.

Known or suspected biliary duct obstruction, sphincter of Oddi disease or dysfunction, and pancreatitis.

Most common adverse reactions are constipation, nausea, and abdominal pain.

Pregnancy: Not established.

Lactation: Not established.

Sphincter of Oddi spasm and pancreatitis.

Patients who should be monitored closely:

• Without a gallbladder
• With new or worsening abdominal pain
• With nausea and vomiting
• With acute biliary pain
• With liver or pancreatic enzyme elevation

Carboxylic acids and derivatives, Prokinetic drugs

Store in a cool & dry place, protect from light. Keep out of the reach of children.